Consensus $14.10. Raises FY19 revenue view to $22.0B-$22.9 from $21.8B-$22.9B, consensus $22.78B. “We continue to generate strong, volume-driven growth for our newer products, while effectively defending our mature products. We are also advancing a record number of first-in-class molecules targeting significant areas of unmet need through our pipeline,” said Robert Bradway, chairman and CEO.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.